Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (51-60 of 791) with videos related to

Pageof 80
Sort By:
Oncology (Williston Park, N.Y.)|May 14, 2008
Management of patients with resistant or refractory chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Leukemia Research|February 5, 2008
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clonesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Blood|October 2, 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Expert Opinion on Investigational Drugs|March 21, 2007
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Leukemia & Lymphoma|March 19, 2009
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1Jorge Cortes, Kim De Keersmaecker
Idrugs : the Investigational Drugs Journal|May 10, 2008
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignanciesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
Molecular resistance: an early indicator for treatment change?Carmen Fava, Hagop Kantarjian, Jorge Cortes
Cancer|October 15, 2010
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsElias Jabbour, Jorge Cortes, Hagop Kantarjian
Leukemia & Lymphoma|October 30, 2004
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of actionElias Jabbour, Hagop Kantarjian, Jorge Cortes
Pageof 80

Showing results (51-60 of 791) with videos related to

Sort By:
Pageof 80
Oncology (Williston Park, N.Y.)|May 14, 2008
Management of patients with resistant or refractory chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Leukemia Research|February 5, 2008
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clonesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Blood|October 2, 2008
Molecular biology of bcr-abl1-positive chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Expert Opinion on Investigational Drugs|March 21, 2007
Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemiaAlfonso Quintás-Cardama, Jorge Cortes
Leukemia & Lymphoma|March 19, 2009
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1Jorge Cortes, Kim De Keersmaecker
Idrugs : the Investigational Drugs Journal|May 10, 2008
Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignanciesAlfonso Quintás-Cardama, Jorge Cortes
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
Molecular resistance: an early indicator for treatment change?Carmen Fava, Hagop Kantarjian, Jorge Cortes
Cancer|October 15, 2010
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsElias Jabbour, Jorge Cortes, Hagop Kantarjian
Leukemia & Lymphoma|October 30, 2004
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of actionElias Jabbour, Hagop Kantarjian, Jorge Cortes
Pageof 80